Group 1 - The company achieved a revenue of 1.142 billion yuan in 2024, representing a year-on-year growth of 9.94% [2] - The net profit attributable to shareholders was 148 million yuan, with a non-recurring net profit of 125 million yuan [2] - The revenue growth was primarily driven by the core business segment of safety services, which generated 959 million yuan, a year-on-year increase of 7.86% [2] Group 2 - The company faced pressure on profit margins due to a slowdown in investment and market demand in the domestic pharmaceutical industry, leading to intensified market competition and a decline in sales order prices [2] - The company has developed several core technology platforms, including toxicological biomarker evaluation and non-clinical safety evaluation systems, and has assisted in nearly 200 innovative drug research services [2] - The company is actively building "AI+" capabilities, focusing on the integration of artificial intelligence with industry scenarios, and is exploring the development of AI-assisted diagnostic systems [3] Group 3 - The company's subsidiary passed the FDA's Good Laboratory Practice (GLP) inspection, enhancing its international service capabilities [3] - The company ranks among the top three in the domestic non-clinical safety evaluation market, indicating a leading position in the industry [3] - Recent government policies supporting innovative drug development and the CRO industry are expected to provide significant growth opportunities for the company [3]
益诺思2024年营收11.42亿元 同比增9.94%